Thomas O. Crawford

Thomas O. Crawford

Neurology | Pediatric Neurology

10753 Falls Road
Pavilion II STE 115
Lutherville, MD 21093

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 87 publications

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Journal: Nature medicine

Published: April 23, 2026

Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway.

Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway.

Journal: Expert review of neurotherapeutics

Published: January 22, 2026

New SMA era: A broad-range tiered assessment of function for the evolving SMA phenotype (EVOLVE-SMA).

New SMA era: A broad-range tiered assessment of function for the evolving SMA phenotype (EVOLVE-SMA).

Journal: Journal of neuromuscular diseases

Published: December 30, 2025

Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients.

Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients.

Journal: Research square

Published: December 11, 2025

A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.

A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.

Journal: Expert review of neurotherapeutics

Published: November 13, 2025

Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients.

Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients.

Journal: Acta neuropathologica communications

Published: November 11, 2025

Electrodiagnostic Studies as a Diagnostic and Prognostic Tool in Acute Flaccid Myelitis.

Electrodiagnostic Studies as a Diagnostic and Prognostic Tool in Acute Flaccid Myelitis.

Journal: Muscle & nerve

Published: August 04, 2025

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Journal: Nature medicine

Published: July 29, 2025

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophy.

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophy.

Journal: Neuromuscular disorders : NMD

Published: June 18, 2025

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophy.

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophy.

Journal: Neuromuscular disorders : NMD

Published: June 18, 2025

Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy.

Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy.

Journal: Neuromuscular disorders : NMD

Published: June 17, 2025

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.

Journal: The Lancet. Neurology

Published: March 25, 2025

Showing 1-12 of 87

Last Updated: 09/26/2026